Corcept Therapeutics (CORT) director offloads stock under 10b5-1 plan

Rhea-AI Filing Summary

Corcept Therapeutics Inc (CORT) director David L. Mahoney reported indirect sales of company common stock on August 18, 2026. A family trust associated with him sold a total of 103,606 shares in multiple open-market transactions at weighted average prices between $116.595 and $119.6775, pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. The filing also reports 26,147 shares of common stock held indirectly through The Black Dog Private Foundation.

Insider Trade Summary 10b5-1

Net Seller: 103,606 shares

Net Sell 5 txns

Insider MAHONEY DAVID L

Role Director

Sold 103,606 shs ($12.25M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	4,984	$117.4716	$585K
Sale	Common Stock F1, F3	91,167	$118.2376	$10.78M
Sale	Common Stock F1, F4	7,055	$118.8817	$839K
Sale	Common Stock F1, F5	400	$119.6381	$48K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,133,539 shares (Indirect, Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust); Common Stock — 26,147 shares (Indirect, The Black Dog Private Foundation)

Footnotes (5)

1. F1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.
2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
5. F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Key Figures

Total shares sold: 103,606 shares Block sale 1: 4,984 shares at $117.4716 per share Block sale 2: 91,167 shares at $118.2376 per share +5 more

8 metrics

Total shares sold 103,606 shares Indirect open-market sales on August 18, 2026 by associated family trust

Block sale 1 4,984 shares at $117.4716 per share Indirect open-market sale on August 18, 2026

Block sale 2 91,167 shares at $118.2376 per share Indirect open-market sale on August 18, 2026

Block sale 3 7,055 shares at $118.8817 per share Indirect open-market sale on August 18, 2026

Block sale 4 400 shares at $119.6381 per share Indirect open-market sale on August 18, 2026

Price range of sales $116.595 to $119.6775 per share Actual trade-price ranges from weighted-average price footnotes

Indirect foundation holdings 26,147 shares Shares of common stock held by The Black Dog Private Foundation

Rule 10b5-1 plan adoption date May 11, 2026 Plan under which August 18, 2026 sales were executed

Key Terms

Rule 10b5-1 plan, weighted average sale price, indirect, open market or private transaction

4 terms

Rule 10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

indirect financial

"ownership_type":"indirect","ownership_code":"I""

open market or private transaction financial

"transaction_code_description":"Sale in open market or private transaction""

FAQ

What insider transactions did CORT report for David L. Mahoney on August 18, 2026?

The report shows that a family trust associated with director David L. Mahoney sold 103,606 shares of Corcept Therapeutics (CORT) common stock on August 18, 2026 in multiple open-market transactions at weighted average prices between $116.595 and $119.6775.

At what prices were the CORT shares sold in Mahoney’s August 18, 2026 transactions?

The sales by the associated family trust occurred at weighted average prices of $117.4716, $118.2376, $118.8817, and $119.6381 per share, with actual trade prices ranging from $116.595 to $119.6775 as disclosed in the footnotes.

How many CORT shares did each transaction involve in Mahoney’s Form 4 filing?

The filing lists four indirect open-market sales: 4,984 shares at $117.4716, 91,167 shares at $118.2376, 7,055 shares at $118.8817, and 400 shares at $119.6381, all of Corcept Therapeutics (CORT) common stock.

Were Mahoney’s CORT share sales under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 11, 2026 and in effect at the time of the August 18, 2026 sales.

How are the sold CORT shares held in Mahoney’s Form 4?

The sold shares are reported as held indirectly by the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, indicating indirect ownership of the Corcept Therapeutics (CORT) common stock through that trust.

What other indirect CORT holdings are disclosed for Mahoney?

The Form 4 discloses that 26,147 shares of Corcept Therapeutics (CORT) common stock are held indirectly through The Black Dog Private Foundation, reported as an indirect ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:30 PM Accepted by SEC EDGAR 08/20/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHONEY DAVID L

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S(1)		4,984	D	$117.4716(2)	1,232,161	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Common Stock	08/18/2026		S(1)		91,167	D	$118.2376(3)	1,140,994	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Common Stock	08/18/2026		S(1)		7,055	D	$118.8817(4)	1,133,939	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Common Stock	08/18/2026		S(1)		400	D	$119.6381(5)	1,133,539	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Common Stock								26,147	I	The Black Dog Private Foundation

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for David L Mahoney	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)